Key result
HIV and ART, particularly protease inhibitors, are linked to increased QT prolongation risk.
Why the study?
Antiretrovirals have increased life expectancy in HIV-positive patients, but the incidence of QT interval prolongation and other arrhythmias has also increased.
What are the risk factors and mechanisms for QT prolongation in HIV-positive patients?
Population
HIV-positive patients
Design
Review article
Authors
Loading...
May support QT monitoring in HIV patients on protease inhibitors; leaves open the need for prospective trials on arrhythmic outcomes.
What are the risk factors and mechanisms for QT prolongation in HIV-positive patients?
Highlights the multifactorial risk of QT prolongation in HIV-positive patients and suggests baseline and follow-up EKG monitoring in susceptible populations.
Liu et al. (2019) conducted a review in HIV infection. HIV infection and antiretroviral therapy was evaluated on QT interval prolongation. HIV infection and antiretroviral therapy, particularly protease inhibitors, along with adjunct medications and chronic inflammation, increase the risk of QT interval prolongation in HIV-positive patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: